Using CRISPR/Cas9 genome editing to facilitate antibiotic discovery in novel Streptomyces species
Using CRISPR/Cas9 genome editing to facilitate antibiotic discovery in novel Streptomyces species
批准号:
BB/X00967X/1
负责人:
Rebecca Devine
金额:
$50.5万
依托单位:
依托单位国家:
英国
项目类别:
Fellowship
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Antibiotics are some of our most important medicines; they treat a range of infectious diseases and are also used to prevent infections in immunocompromised patients such as those undergoing chemotherapy or organ transplant surgery. Unfortunately, microorganisms are increasingly developing resistance to our current antibiotics, meaning the antibiotics no longer work as effectively. New antibiotics that have activity against resistant microorganisms are urgently needed. Around two-thirds of currently used antibiotics were developed from compounds made naturally by soil-dwelling bacteria like Streptomyces. Streptomyces are thought to produce many antimicrobial compounds in the environment, but in the lab, they only usually make a few. This means many more antimicrobial molecules remain to be discovered from Streptomyces if we can find ways to switch on these 'silent' pathways in the lab.This project will use genetic engineering to switch on the production of antibiotics in Streptomyces formicae, a new strain isolated from the nests of Tetraponera penzigi plant-ants. S. formicae is a talented strain, with the potential to produce many antimicrobial molecules. So far, only one has been characterised; a new family of antibiotics called the formicamycins which are potent inhibitors of resistant microorganisms. By deleting the genes responsible for formicamycin production, we have shown that S. formicae starts to produce previously 'silent' compounds, including more new antimicrobials that have activity against resistant microorganisms. In this fellowship, I will seek to characterise these new antimicrobials and determine their clinical potential. I also aim to understand how the antimicrobial molecules are made by S. formicae and why deletion of the formicamycin pathway induces the production of these previously silent molecules. By understanding how these silent pathways are switched on, we can determine whether the same approach could be used in the many hundreds of other Streptomyces strains isolated across the globe, facilitating the discovery of many new antimicrobial molecules.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
全基因组CRISPR/Cas9文库筛选发现IGF1R通过抑制细胞焦亡途径诱导结直肠癌奥沙利铂耐药的机制研究
-
批准号:2026JJ80578
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:杨熙华
-
依托单位:
CRISPR/Cas9精确编辑NOTCH2NLC基因GGC重复扩增突变的治疗策略探究
-
批准号:2026JJ50082
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:谢妮娜
-
依托单位:
利用CRISPR/Cas9和单细胞多组学技术探索IRF-1介导代谢重编程在肝缺血再灌注损伤后肝脏再生中的作用机制
-
批准号:2026JJ50622
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:罗静
-
依托单位:
基于CRISPR/Cas9基因编辑技术及雌核发育技术快速获得无肌间刺金背鲤新种质的研究
-
批准号:2026JJ30134
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:李俊
-
依托单位:
基于CRISPR/Cas9筛选探究Uchl5/Ep300信号轴调控脓毒症心肌病的分子机制
-
批准号:JCZRLH202600693
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
CRISPR插删突变介导的Cas9定向进化新技术建立
-
批准号:Z25H160016
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:谢安勇
-
依托单位:
基于CRISPR/Cas9编辑人肝类器官抗纤维化小分子化合物高通量筛选及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:朱昱
-
依托单位:
基于CRISPR/Cas9文库探索Ambra1调控m7G修饰促进肝细胞癌对TKIs耐药的机制研究
-
批准号:2025JJ70216
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:伍焱平
-
依托单位:
利用CRISPR/Cas9敲低食蟹猴大脑亨廷顿
基因治疗亨廷顿病的可行性和安全性
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:童辉纯
-
依托单位:
基于非病毒基因载体的CRISPR/Cas9基因
编辑疗法治疗RDEB
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:曾明
-
依托单位: